Physician profile
Eshwar Ramadas
NPI 1134548829
$8,753.91
in general payments reported to CMS, 2019-2025
39 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $1,400 · 2021: $1,985 · 2022: $1,610 · 2023: $628 · 2024: $1,157 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,180.92 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $921.11 | 2019-2025 | |
| Novo Nordisk INC | $897.43 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $770.35 | 2019-2025 | |
| Lilly USA, LLC | $534.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.66 | 2019-2025 | Jardiance |
| Amgen INC. | $311.40 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $288.85 | 2020-2022 | |
| Abbott Laboratories | $220.18 | 2022-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $211.43 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company Ltd. | $202.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.53 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $184.21 | 2019-2021 | |
| Dexcom, INC. | $172.81 | 2022-2024 | Dexcom G7 Gss (161) |
| Novartis Pharmaceuticals Corporation | $172.42 | 2022-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eshwar Ramadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.